• Publications
  • Influence
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma
Summary:Factors affecting progenitor cell mobilisation in patients with non-Hodgkin's lymphoma (NHL) are incompletely understood. We have analysed factors predicting mobilisation failure in 97Expand
  • 109
  • 6
Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences
The objective of this study was to evaluate etiology and consequences of neutropenic fever in AML patients. Two hundred and ninety neutropenic periods following chemotherapy in 84 AML patients wereExpand
  • 57
  • 2
Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis
Abstract We compared biomarkers and their changes as predictors for bacteremia and severe sepsis during neutropenic fever after intensive chemotherapy in hematological patients. Serum C-reactiveExpand
  • 22
  • 2
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
Summary:Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY. We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adultExpand
  • 28
  • 1
Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
Objectives:  Limited data are available on the cardiac effects of high‐dose cyclophosphamide (CY) in patients with non‐Hodgkin's lymphoma (NHL). We prospectively assessed the cardiac effects ofExpand
  • 25
  • 1
Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia
Abstract Objective: To compare semi-quantitative procalcitonin with C-reactive protein in predicting bacteraemia in haematological patients with neutropenic fever. Methods: A total of 77 patientsExpand
  • 51
  • 1
Blood graft composition after plerixafor injection in patients with NHL
Plerixafor is used to mobilize CD34+ hematopoietic stem cells from bone marrow to circulation. Limited data are available in regard to graft cellular content collected after plerixafor.
  • 28
  • 1
Severe sepsis in autologous stem cell transplant recipients: Microbiological aetiology, risk factors and outcome
Infectious complications are the main reason for early treatment-related mortality after autologous stem cell transplantation (ASCT). We evaluated retrospectively microbiological aetiology, riskExpand
  • 31
  • 1
Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?
Summary:About 10–30% of patients with non-Hodgkin's lymphoma (NHL) intended to receive high-dose therapy are difficult to mobilise. Damage to the stem cell pool caused by previous chemotherapy may beExpand
  • 19
  • 1
Outcome of progressive disease after autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a nation‐wide survey
Abstract:  Objectives: To analyse outcome and prognostic factors in non‐Hodgkin's lymphoma (NHL) patients who progress after autologous stem cell transplantation (ASCT). Patients: Altogether 115Expand
  • 11
  • 1